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Purpose: Behçet’s disease (BD) theoretically affects all sizes and types of blood 
vessels and results in multi-organ involvement. However, renal BD has not been 
fully characterized, though the kidneys are histologically rich in blood vessels. 
Materials and Methods: A total of 2007 patients who fulfilled the diagnostic cri-
teria for BD were enrolled in this study. We reviewed the medical records and test 
results of the BD patients and used univariate and multivariate logistic regression 
analyses to determine the clinical significance of renal involvement in BD. Re-
sults: Among the 2007 BD patients, we noted hematuria in 412 (20.5%) and pro-
teinuria in 29 (1.4%). Univariate analysis showed that the BD patients with hema-
turia were predominantly female and older, had higher erythrocyte sedimentation 
rates (ESRs), and more frequently presented with genital ulcerations. BD patients 
with proteinuria had higher ESR levels compared to BD patients without protein-
uria. In the multivariate analysis, age, sex, and ESR were found to be significantly 
associated with hematuria in BD patients, whereas only ESR was associated with 
proteinuria in BD patients. We also found that IgA nephropathy was the most 
common pathologic diagnosis in 12 renal BD patients who underwent renal biop-
sies. Conclusion: We suggest that routine urinalysis and serum renal function tests 
be performed for the early detection of renal BD, especially in older female BD 
patients with recurrent hematuria, high ESR levels, and frequent genital ulcers, as 
well as in BD patients with proteinuria and high ESR levels.
Key Words:   Behçet’s disease, renal involvement, hematuria, proteinuria, IgA ne-
phropathy 
INTRODUCTION
Behçet’s disease (BD) theoretically affects all sizes and types of blood vessels and 
results in multi-organ involvement.1 Renal BD has not been fully characterized, al-
though kidneys are histologically rich in blood vessels and receive approximately 
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pyelogram, ultrasonographic examination of the abdomen 
and pelvis, cytologic examination of the urine, and lab tests 
including complement levels and the quantitative evalua-
tion of serum immunoglobulins. 
Chi-square tests, Fisher’s exact tests, and Mann-Whitney 
U tests were applied to assess differences between the clini-
cal features of BD patients with hematuria and/or proteinuria 
and those with normal urinalyses. The strength of associa-
tions among urinary abnormalities, demographics, clinical 
symptoms, and laboratory characteristics are expressed as 
odds ratios (ORs) and 95% confidence intervals (CI). Logis-
tic regression models were used, and variables with p<0.15 
in the univariate analysis were included in the multivariate 
analysis. All analyses were performed using SAS software 
version 9.1.3 (SAS Institute Inc., Cary, NC, USA). Differ-
ences were considered statistically significant when the p-
value was less than 0.05. 
RESULTS
 
Clinical characteristics of 2007 BD patients
Among the 2007 patients, the following symptoms were 
observed in descending order of frequency: recurrent oral 
ulcers in all 2007 patients (100%), genital ulcers in 1688 
patients (84.1%), cutaneous involvement in 1579 patients 
(78.7%), arthritis in 1057 patients (52.7%), and ocular in-
volvement in 682 patients (34.0%) (Table 1). Gastrointesti-
nal system involvement was noted in 218 patients (10.9%), 
central nervous system involvement in 50 patients (2.5%), 
a positive pathergy test in 47 patients (2.3%), and epididy-
mitis in 27 patients (1.4%). Positive HLA B51 genotype 
was identified in 271 patients (13.5%).
BD patients with renal manifestations
Among the 2007 BD patients, hematuria was seen in 412 
patients [20.5%; 48 males and 364 females (1 : 7.6), with a 
median age of 48 years and ages ranging from 17 to 76 
years] and proteinuria in 29 patients [1.4%; 11 males and 
18 females (1 : 1.6), with a median age of 42 years and 
ages ranging from 23 to 74 years]. Five of the 2007 BD pa-
tients were found to have both hematuria and proteinuria. 
The following symptoms were observed in descending or-
der of frequency in the 412 BD patients with hematuria (Ta-
ble 1): recurrent oral ulcers in all 412 patients (100%), genital 
ulcers in 362 patients (87.9%), cutaneous involvement in 322 
patients (78.2%), arthritis in 231 patients (56.1%), and ocular 
20% of the cardiac output.2,3 The main causes of renal BD re-
portedly include AA type amyloidosis, glomerulonephritis, 
renal vascular involvement, and interstitial nephritis.2,3 The 
clinical manifestations of renal BD range from asymptomatic 
hematuria and/or proteinuria to end-stage renal disease.2 Ak-
polat, et al.2 have demonstrated that renal involvement in BD 
seems to be more frequent than has been reported, and most 
renal BD patients have an indolent disease course. Histopath-
ologically, minor glomerular changes and microscopic vas-
cular disease are most commonly observed in renal BD pa-
tients with a mild clinical course.2 
In this study, we retrospectively reviewed the clinical 
characteristics of 2007 Korean BD patients and analyzed 
the results of their urinalyses. Herein we also discuss the 
findings of light microscopy, immunofluorescence tests, 
and electron microscopy in 12 BD patients who underwent 
renal biopsy.
MATERIALS AND METHODS
　　　
Two thousand and seven patients (584 males and 1423 fe-
males (1 : 2.4); median age, 42 years; age ranging, 13 to 82 
years) who were registered at the BD Specialty Clinic of 
Severance Hospital between January 2009 and December 
2010 and fulfilled the diagnostic criteria for BD were en-
rolled in this study. The criteria used for BD diagnosis are 
outlined by the International Study Group for BD.4 A diag-
nosis of hematuria was made on the basis of microscopic 
examination of urine sediment, with a count of five erythro-
cytes/high power field (1 field, 400× magnification) appear-
ing more than two times in one year or three times in six 
months considered positive.5 Among the 2007 BD patients, 
12 patients underwent renal biopsies, and two nephrologists 
made the diagnosis of renal disease through biopsy confir-
mation, taking into account the findings of light microsco-
py, immunofluorescence tests, and electron microscopy.
Patient medical records were reviewed in order to investi-
gate the clinical characteristics of BD, the results of the uri-
nalyses, and other laboratory test results. Lab tests included 
complete blood count, blood glucose level, renal and liver 
function tests, erythrocyte sedimentation rate (ESR; normal 
range, ≤20 mm/hour), C-reactive protein (CRP; normal 
range, ≤0.8 mg/dL), anti-streptolysin O titer, rheumatoid 
factor, antinuclear antibodies, sexually transmitted infection 
work-up, and HLA B51 genotype. Additionally, patients 
with hematuria and/or proteinuria underwent intravenous 
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patient (3.5%). No patient experienced central nervous sys-
tem involvement. Positive HLA B51 genotype was identi-
fied in 4 patients (13.8%).
Univariate analysis
The univariate analysis (Table 2 and 3) showed that BD pa-
tients with hematuria were predominantly female (OR, 
3.84; 95% CI, 2.79-5.28; p<0.001), older (OR, 1.01; 95% CI, 
1.00-1.02; p=0.03), had higher ESR levels (OR, 1.02; 95% 
CI, 1.01-1.02; p<0.001), and more frequently experienced 
genital ulcerations (OR, 1.47; 95% CI, 1.06-2.03; p=0.02) 
compared with BD patients without hematuria. BD patients 
with proteinuria had higher ESR levels (OR, 1.03; 95% CI, 
1.02-1.04; p<0.001) compared to BD patients without pro-
teinuria. However, no association was found between pro-
teinuria in BD patients and sex (p=0.30), age (p=0.24), or 
genital ulceration (p=0.84).
Multivariate analysis
The variables with a p-value <0.15 in the univariate com-
parisons of BD patients with and without hematuria (Table 
3) as well as BD patients with and without proteinuria (Ta-
ble 2) were considered for inclusion in the multivariate 
involvement in 135 patients (32.8%). Gastrointestinal system 
involvement was noted in 45 patients (10.9%), vascular sys-
tem involvement in 17 patients (4.1%), central nervous sys-
tem involvement in 8 patients (1.9%), and epididymitis in 3 
patients (0.7%). Positive HLA B51 genotype was identified 
in 56 patients (13.6%) and 14 patients (3.4%) had a positive 
pathergy test. 
Using chi-square tests, Fisher’s exact tests, and Mann-
Whitney U tests, hematuria was found to be more frequent 
in female BD patients (p<0.0001) and BD patients with 
higher ESR (p<0.0001), CRP (p<0.0001), and anti-strepto-
lysin O titer (ASO) (p=0.040) levels. Also, BD patients 
with hematuria more frequently experienced genital symp-
toms (p=0.019). 
Among the 29 BD patients with proteinuria, the follow-
ing symptoms were observed in descending order of fre-
quency (Table 2): recurrent oral ulcers in all 29 patients 
(100%), genital ulcers in 24 patients (82.8%), cutaneous in-
volvement in 23 patients (79.3%), arthritis in 11 patients 
(37.9%), and ocular involvement in 5 patients (17.2%). Vas-
cular involvement was noted in 3 patients (10.3%), a posi-
tive pathergy test in 2 patients (13.8%), gastrointestinal sys-
tem involvement in 1 patient (3.5%), and epididymitis in 1 
Table 1. Comparison of Demographic Characteristics, Symptoms, and Laboratory Findings of BD Patients Grouped According 
to the Presence of Hematuria 
2007 BD patients
BD patients with hematuria, 
n (%)
BD patients without 
hematuria, n (%)
p value
Age*        47 (13-82)       48 (17-76)         47 (13-82)   0.059
Sex <0.0001
    Male    584 (29.1)     48 (11.7)    536 (33.6)
    Female  1423 (70.9)   364 (88.3)  1059 (66.4)
Oral ulcers 2007 (100)  412 (100) 1595 (100)   1
Genital ulcers  1688 (84.1)   362 (87.9)    1326 (83.13)   0.019
Skin lesions  1579 (78.7)   322 (78.9)  1257 (78.8)   0.77
Eye lesions    682 (34.0)   135 (32.8)    547 (34.3)   0.56
Arthritis  1057 (52.7)   231 (56.1)    826 (51.8)   0.12
GI involvement    218 (10.9)     45 (10.9)    173 (10.9)   0.96
Vascular involvement    88 (4.4)   17 (4.1)    71 (4.5)   0.77
CNS involvement    50 (2.5)     8 (1.9)    42 (2.6)   0.42
Epididymitis    27 (1.4)     3 (0.7)    24 (1.5)   0.22
Positive pathergy test    47 (2.3)   12 (2.9)    35 (2.2)   0.39
Positive HLA-B51    271 (13.5)     56 (13.6)    214 (13.4)   0.82
ASO*     47.7 (0-491)       49.3 (0-410.9)      46.8 (0-491)   0.040
ESR (mm/hour)*        16 (0-120)       22 (2-120)         14 (0-120) <0.0001
CRP (mg/dL)*        0.3 (0-33.5)          0.3 (0.1-33.5)         0.2 (0-19.7) <0.0001
GI, gastrointestinal system; CNS, central nervous system; ASO, anti-streptolysin O titer; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; BD, 
Behçet’s disease.
*Data are presented as median values (minimum-maximum).
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CRP (p=0.12). Among these factors, age (OR, 1.01; 95% 
CI, 1.00-1.02; p=0.034), sex (OR, 3.60; 95% CI, 2.60-4.98; 
p<0.001) and ESR (OR, 1.01; 95% CI, 1.01-1.02; p<0.001) 
were found to be significantly associated with hematuria in 
analyses. In comparing BD patients with and without he-
maturia, multivariate analyses were performed including 
the following variables: age (p=0.03), sex (p<0.001), geni-
tal ulcers (p=0.02), arthritis (p=0.12), ESR (p<0.001), and 
Table 2. Univariate and Multivariate Comparisons of BD Patients with and without Proteinuria
BD patients with 
proteinuria, n (%)
BD patients 
without 
proteinuria, n (%)
Univariate Multivariate
OR (95% CI) p value OR (95% CI) p value
Age*    42 (23-74)     47 (13-82) 0.98 (0.95-1.01) 0.24
Sex 0.67 (0.31-1.42) 0.30
    Male    11 (37.9)   573 (29.0)
    Female    18 (62.1) 1405 (71.0)
Oral ulcers    29 (100) 1978 (100)
Genital ulcers    24 (82.8) 1664 (84.1) 0.90 (0.34-2.39) 0.84
Skin lesions    23 (79.3) 1556 (78.7) 1.04 (0.42-2.57) 0.93
Eye lesions      5 (17.2)   677 (34.2) 0.40 (0.15-1.05) 0.06 0.40 (0.15-1.07)   0.067
Arthritis    11 (37.9) 1046 (52.9) 0.55 (0.26-1.16) 0.12 0.53 (0.25-1.13) 0.10
GI involvement      1 (3.5)   217 (11.0) 0.29 (0.04-2.14) 0.23
Vascular involvement      3 (10.3)     85 (4.3) 2.57 (0.76-8.66) 0.13 1.87 (0.51-6.79) 0.34
CNS involvement      0 (0)     50 (2.53) 0.94 (0.00-5.42) 0.96
Epididymitis      1 (3.5)     26 (1.3)   2.68 (0.35-20.45) 0.34
Positive pathergy test      2 (6.9)     45 (2.3) 3.18 (0.73-13.8) 0.12   2.86 (0.63-12.97) 0.17
Positive HLA-B51      4 (13.8)   267 (13.5) 1.03 (0.35-2.97) 0.96
ASO* 55.7 (25-491)  47.4 (0-410.9) 1.00 (1.00-1.00) 0.97
ESR (mm/hour)*    40 (2-107)     16 (0-120)† 1.03 (1.02-1.04) <0.001 1.03 (1.02-1.04) <0.001
CRP (mg/dL)*   1.0 (0.1-25.1)    0.2 (0-33.5)† 1.00 (1.00-1.00) 0.95
GI, gastrointestinal system; CNS, central nervous system; ASO, anti-streptolysin O titer; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; BD, 
Behçet’s disease; OR, odds ratio; CI, confidence intervals.
*Data are presented as median values (minimum-maximum). 
†p<0.0001; p<0.15 (numbers in bold) were considered for inclusion in the multivariate analyses.
Table 3. Univariate and Multivariate Comparisons of BD Patients with and without Hematuria 
Univariate Multivariate
OR (95% CI) p value OR (95% CI) p value
Age (yrs) 1.01 (1.00-1.02) 0.03 1.01 (1.00-1.02)   0.034
Sex 3.84 (2.79-5.28) <0.001 3.60 (2.60-4.98) <0.001
Genital ulcers 1.47 (1.06-2.03) 0.02 1.18 (0.84-1.65) 0.34
Skin lesions 0.96 (0.74-1.25) 0.77
Eye lesions 0.93 (0.74-1.18) 0.56
Arthritis 1.19 (0.96-1.48) 0.12 1.10 (0.88-1.38) 0.42
GI involvement 1.01 (0.71-1.43) 0.97
Vascular involvement 0.92 (0.54-1.59) 0.77
CNS involvement 0.73 (0.34-1.57) 0.42
Epididymitis 0.48 (0.14-1.60) 0.23
Positive pathergy test 1.34 (0.69-2.60) 0.39
Positive HLA-B51 1.04 (0.76-1.42) 0.82
ASO 1.00 (1.00-1.00) 0.51
ESR (mm/hour) 1.02 (1.01-1.02) <0.001 1.01 (1.01-1.02) <0.001
CRP (mg/dL) 1.01 (1.00-1.02) 0.12 1.01 (0.99-1.02) 0.34
GI, gastrointestinal system; CNS, central nervous system; ASO, anti-streptolysin O titer; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; BD, 
Behçet’s disease; OR, odds ratio; CI, confidence intervals.
Variables with p<0.15 (numbers in bold) on univariate analysis were considered for inclusion in the multivariate analyses.
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(58.3%) had arthritis, and 3 patients (25%) had ocular in-
volvement. A positive pathergy test was found in 2 patients 
(16.7%), vascular involvement in 1 patient (8.3%), and gas-
trointestinal system involvement in 1 patient (8.3%). No 
patient experienced central nervous system involvement or 
epididymitis. Positive HLA B51 genotype was noted in 3 
patients (25%).
The median age at BD onset of the 12 BD patients was 
37 (range: 19-54) years (Table 4). The median duration be-
tween BD onset and kidney biopsy was 10.5 (range: 7-18) 
years. The following pathologic findings were observed in 
descending order of frequency in 12 BD patients (Table 5): 
IgA nephropathy in 8 patients (66.7%), mild arteriosclero-
sis in 3 patients (25%), minor glomerular changes in 3 pa-
tients (25%), crescentic glomerulonephritis in 1 patient 
(8.3%), and diabetic diffuse and nodular glomerulosclerosis 
in 1 patient (8.3%). All 3 BD patients with mild arterioscle-
rosis also had pathologic findings of IgA nephropathy. Sev-
en of the 12 BD patients (58.3%) had no specific symptoms 
suggestive of BD renal involvement or any other kind of 
kidney problems (Table 6), whereas generalized edema was 
noted in 2 patients (16.7%), general weakness or frequent 
dizziness in 2 patients (16.7%), and foamy urine in 1 pa-
tient (8.3%). 
Systemic therapies were provided to the 12 BD patients 
BD patients. However, neither genital ulcers (OR, 1.18; 
95% CI, 0.84-1.65; p=0.34) nor arthritis (OR, 1.10; 95% 
CI, 0.88-1.38; p=0.42) was significantly associated with he-
maturia in BD patients on multivariate analysis.
In comparing BD patients with and without proteinuria, 
multivariate analyses were performed and included the fol-
lowing variables: eye lesions (p=0.064), arthritis (p=0.12), 
vascular involvement (p=0.13), positive pathergy test (p= 
0.12), and ESR (p<0.001). Only ESR (OR, 1.03; 95% CI, 
1.02-1.04; p<0.001) was associated with proteinuria in BD 
patients. Eye lesions (OR, 0.40; 95% CI, 0.15-1.07; p=0.067), 
arthritis (OR, 0.53; 95% CI, 0.25-1.13; p=0.10), vascular in-
volvement (OR, 1.87; 95% CI, 0.51-6.79; p=0.34), and a 
positive pathergy test (OR, 2.86; 95% CI, 0.63-12.97; 
p=0.17) did not show any significant association. 
Results of kidney biopsies
Among the 2007 BD patients, 12 patients [two males and 
ten females (1 : 5), with a median age of 48.5 years and 
ages ranging from 28 to 68 years] underwent renal biopsy 
(Table 4). All 12 patients (100%) experienced recurrent oral 
ulcers, 11 patients (91.7%) had genital ulcers, 10 patients 
(83.3%) had cutaneous involvement (erythema nodosum-
like skin lesions in 6 patients, papulopustular lesions in 5 
patients, and 1 had both types of skin lesions), 7 patients 
Table 4. Clinical Features of 12 Patients with Behçet’s Disease (BD) Who Underwent Kidney Biopsy
Clinical findings
Patients with BD
1 2 3 4 5 6 7 8 9 10 11 12
Sex F F F F F F F M F F M F
Age (yrs) 68 37 61 56 47 45 49 50 48 47 53 28
Age at BD onset (yrs) 54 22 48 37 37 33 30 38 27 40 44 19
Period between BD onset and 
  the kidney biopsy (yrs)
  9 14 10 12   9 11 13 11 18   7 10   9
Oral ulcers + + + + + + + + + + + +
Genital ulcers + + + + + + + + + + + +
EN-like lesions + - + - + + + + + - - -
Pseudofolliculitis - + - + - - + - - - + +
Eye lesions - - - - - - + - + + - -
Vascular involvement - - - - + - - - - - - -
Arthritis - - + - + + - - + + + +
CNS involvement - - - - - - - - - - - -
GI involvement - - + - - - - - - - - -
Epididymitis - - - - - - - - - - - -
Pathergy test - + - - - - - - - - - +
HLA-B51 genotyping - - - - + - + - - - - +
Proteinuria + + - + + - - - + - + +
Hematuria - + - + + + + + - + + +
BUN/Cr elevation + + - + - - - + - - - -
EN, erythema nodosum; CNS, central nervous system; GI, gastrointestinal system; +, present; −, absent.
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nal BD patients were determined to be amyloidosis (n=108; 
42.7%), glomerulonephritis (n=88; 34.8%), renal macro-
scopic/microscopic vascular disease (n=55; 21.7%), and in-
terstitial nephritis (n=5; 2.0%). The authors suggested that 
BD patients with vascular involvement have a high risk of 
amyloidosis, which is the most common cause of renal fail-
ure in BD patients.3 Also, routine urinalysis and measure-
ment of serum creatinine level have been proposed for ear-
ly diagnosis of renal BD.3 In addition, Kavala, et al.7 reported 
that 16.1% (n=34) of BD patients (n=211) were revealed to 
have renal involvement as microalbuminuria in 11.1% (n=22) 
and proteinuria in 5.6% (n=12). The authors described that 
central nervous system involvement and disease duration of 
≥10 years was significantly associated with the risk of mi-
croalbuminuria. 
In the present study, we retrospectively reviewed the med-
ical records of a total of 2007 BD patients and analyzed the 
and their treatment responses are summarized in Table 6. 
Ten (83.3%) of the 12 BD patients had stable renal disease, 
1 patient (8.3%) experienced disease progression and even-
tually died despite systemic prednisolone and colchicine 
treatment and hemodialysis, and 1 patient (8.3%) experi-
enced disease progression despite treatment with systemic 
furosemide, hydrochlorothiazide, losartan potassium, and 
thioctic acid. 
DISCUSSION
Since Oshima, et al.6 first reported hematuria and protein-
uria associated with BD, AA-type amyloidosis, glomerulo-
nephritis, and renal vascular disease have been accepted as 
renal manifestations of BD.2,3 According to a previous re-
port,3 the types of renal involvement among 253 cases of re-
Table 6. Clinical Manifestations and Treatment Responses of 12 Patients with Behçet’s Disease (BD) Who Underwent Kidney 
Biopsy
Pt. No. Clinical manifestations Therapy Response
  1 Generalized edema Prednisolone, colchicine, hemodialysis Progressed, death
  2 Generalized edema Furosemide, hydrochlorothiazide, losartan potassium, thioctic acid Progressing
  3 Frequent dizziness Prednisolone, colchicine, azathioprine, mesalazine, potassium chloride Stationary
  4 Asymptomatic
Furosemide, hydrochlorothiazide, losartan potassium, thioctic acid, 
  polystyrene sulfonate calcium
Stationary
  5 Asymptomatic
Prednisolone, colchicine, rebamipide, furosemide, olmesartan 
  medoxomil, nisoldipine, sulodexide  
Stationary
  6 Asymptomatic Prednisolone, colchicine Stationary
  7 Asymptomatic Colchicine Stationary
  8 Asymptomatic Prednisolone, cyclophosphamide Stationary
  9 Foamy urine Prednisolone, colchicine Stationary
10 General weakness Colchicine, rebamipide Stationary
11 Asymptomatic Colchicine, rebamipide Stationary
12 Asymptomatic Prednisolone, colchicine, rebamipide, aceclofenac Stationary
Table 5. Immunohistopathologic Features of 12 Patients with Behçet’s Disease (BD) Who Underwent Kidney Biopsy  
Pt. No. Pathologic findings Immunofluorescence tests
  1 Crescentic glomerulonephritis and early IgA nephropathy IgG, IgA, C3, and fibrinogen
  2 Diabetic diffuse and nodular glomerulosclerosis IgG, IgA, C3, lambda, and fibrinogen
  3
Glomerular minor change with focal mild tubular atrophy and 
  interstitial fibrosis
IgG and IgM
  4 IgA nephropathy, subclass V IgG, IgA, C3, and fibrinogen
  5 IgA nephropathy, subclass III and mild arteriosclerosis IgG, IgA, C3, kappa, lambda, and fibrinogen
  6 IgA nephropathy, subclass III and mild arteriosclerosis IgG, IgM, IgA, C3, C4, lambda, and fibrinogen
  7 IgA nephropathy, subclass I IgA and C3
  8 IgA nephropathy, subclass III and mild arteriosclerosis IgA, C3, lambda, fibrinogen
  9 Minor glomerular change -
10 Minor glomerular change C3 and fibrinogen
11 IgA nephropathy, subclass II IgG, IgA, IgM, C3, C4, C1q, and fibrinogen
12 IgA nephropathy, subclass IV IgG, IgA, IgM, C3, C4, C1q, and fibrinogen
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through the inhibition of enhanced monocyte chemotactic 
protein-1 and intercellular adhesion molecule-1 expres-
sion.3,16 However, routine administration of colchicine for 
BD patients with hematuria, proteinuria, or biopsy-proven 
glomerular lesions requires further investigation.  
In this study, we analyzed risk factors associated with he-
maturia and proteinuria in 2007 Korean BD patients and 
demonstrated that IgA nephropathy was the most common 
pathologic diagnosis in 12 renal BD patients who under-
went renal biopsies. Our study group previously reported 
the clinical characteristics of 30 BD patients diagnosed 
with aneurysms or pseudoaneurysms in major arterial sys-
tems.17 One patient with multiple saccular aneurysms of the 
renal arteries was already included in the previous report17 
therefore, this patient was excluded in the present study. 
The high prevalence of hematuria or IgA nephropathy in 
BD patients may be the result of regional differences in the 
manifestations of BD or coincidental findings of BD and 
hematuria or IgA nephropathy. Based on our data, we rec-
ommend routine urinalysis and serum renal function tests 
as well as early consultation with a nephrologist for the di-
agnosis of renal BD, especially in older female patients 
with hematuria, high ESR levels, and frequent genital ul-
cers or BD patients with proteinuria and high ESR levels. 
In addition, we believe that our data can be effectively used 
as a clinical reference for further investigations into the 
pathogenetic similarities and differences between BD and 
IgA nephropathy in the Asian-Pacific BD population. 
ACKNOWLEDGEMENTS
This study was supported by a grant of the Korea Health-
care Technology R&D Project, Ministry of Health & Wel-
fare, Republic of Korea (A080588).
REFERENCES
1. Sakane T, Takeno M, Suzuki N, Inaba G. Behçet’s disease. N Engl 
J Med 1999;341:1284-91.
2. Akpolat T, Akkoyunlu M, Akpolat I, Dilek M, Odabas AR, Ozen 
S. Renal Behçet’s disease: a cumulative analysis. Semin Arthritis 
Rheum 2002;31:317-37.
3. Akpolat T, Dilek M, Aksu K, Keser G, Toprak O, Cirit M, et al. 
Renal Behçet’s disease: an update. Semin Arthritis Rheum 2008; 
38:241-8.
4. Criteria for diagnosis of Behçet’s disease. International Study 
Group for Behçet’s Disease. Lancet 1990;335:1078-80.
patients’ data using univariate and multivariate logistic re-
gression analyses to determine the clinical significance of 
renal involvement in BD. Among the 2007 BD patients, he-
maturia was identified in 412 patients (20.5%) while pro-
teinuria was noted in 29 patients (1.4%). The univariate 
analysis showed that the BD patients with hematuria were 
predominantly female and older, had higher ESR levels, 
and more frequently experienced genital ulcerations com-
pared to BD patients without hematuria. BD patients with 
proteinuria had higher ESR levels compared to BD patients 
without proteinuria. Multivariate analysis revealed that age, 
sex, and ESR were significantly associated with hematuria 
in BD patients, whereas only ESR was associated with pro-
teinuria in BD patients. Male gender has been considered a 
risk factor for all types of renal involvement in BD patients.2 
However, our study demonstrated that female gender was a 
risk factor for hematuria in BD patients, but not for protein-
uria. We suspect that regional differences in the male to fe-
male ratio of BD patients might contribute to the marked 
female predominance in cases of hematuria.  
Many types of glomerulonephritis have been reported to 
be associated with BD;2,3,7-10 however, the exact pathogene-
sis remains unclear. The suggested pathogenesis of glomer-
ulonephritis in BD patients includes the deposition of im-
mune complexes, IgA, and anti-neutrophilic cytoplasmic 
antibodies.11-13 Cumulative analyses by Akpolat, et al.2,3 
demonstrated that only 6 (6.8%) of 88 BD patients with pa-
thology-proven glomerulonephritis had IgA nephropa-
thy.8-10 Our study demonstrated that IgA nephropathy was 
the most common pathologic findings among 12 BD pa-
tients who underwent renal biopsies. IgA nephropathy is 
the most common form of glomerulonephritis, with a prev-
alence ranging from 10% in North American renal biopsies 
to 30-40% in the Asian-Pacific area.14,15 
Several types of glomerular lesions can be found in BD 
and these lesions are probably the most common manifesta-
tion of renal disease observed in BD patients.2 Although 
current treatment options for renal BD are not evidence-
based, corticosteroids, colchicine, azathioprine, and cyclo-
phosphamide have been used for the treatment of glomeru-
lar lesions in BD.3 In our study, a majority of the 12 BD 
patients who underwent renal biopsies had indolent courses 
of renal diseases with systemic colchicine treatment with or 
without concomitant corticosteroids and azathioprine. It has 
been suggested that colchicine may prevent extracellular 
matrix and amyloid accumulation as well as various renal 
injuries via its anti-inflammatory action, which occurs 
Sung Bin Cho, et al.
Yonsei Med J   http://www.eymj.org   Volume 54   Number 1   January 2013196
shi Y. IgA nephritis in Behçet’s disease: case report and review of 
the literature. Clin Nephrol 1990;34:52-5.
12. Yang CW, Park IS, Kim SY, Chang YS, Yoon YS, Bang BK, et al. 
Antineutrophil cytoplasmic autoantibody associated vasculitis and 
renal failure in Behçet disease. Nephrol Dial Transplant 1993;8: 
871-3.
13. Khan IH, Catto GR, MacLeod AM. Antineutrophil cytoplasmic 
antibody associated vasculitis and renal failure in Behçet’s disease. 
Nephrol Dial Transplant 1994;9:332.
14. Lehner T, Batchelor JR, Challacombe SJ, Kennedy L. An immu-
nogenetic basis for the tissue involvement in Behçet’s syndrome. 
Immunology 1979;37:895-900.
15. Glassock RJ, Adler SG, Ward HJ, Cohen AH. Primary glomerular 
disease. In: Brenner BM, Rector FC, editors. The kidney. Phila-
delphia: WB Saunders; 1991. p.1203-9. 
16. Li JJ, Lee SH, Kim DK, Jin R, Jung DS, Kwak SJ, et al. Colchi-
cine attenuates inflammatory cell infiltration and extracellular ma-
trix accumulation in diabetic nephropathy. Am J Physiol Renal 
Physiol 2009;297:F200-9. 
17. Cho SB, Kim T, Cho S, Shim WH, Yang MS, Bang D. Major arte-
rial aneurysms and pseudoaneurysms in Behçet’s disease: results 
from a single centre. Scand J Rheumatol 2011;40:64-7. 
5. Higashihara E, Nishiyama T, Horie S, Marumo K, Mitarai T, 
Koyama T, et al. Hematuria: definition and screening test meth-
ods. Int J Urol 2008;15:281-4.
6. Oshima Y, Shimizu T, Yokohari R, Matsumoto T, Kano K, Kaga-
mi T, et al. Clinical Studies on Behçet’s Syndrome. Ann Rheum 
Dis 1963;22:36-45.
7. Kavala M, Menteş F, Kocaturk E, Ergin H, Zindanci I, Can B, et 
al. Microalbuminuria as an early marker of renal involvement in 
Behcet’s disease: it is associated with neurological involvement 
and duration of the disease. J Eur Acad Dermatol Venereol 
2010;24:840-3. 
8. Numo R, Lapadula G, Covelli M, Telrizzi N. Kidney involvement 
in a series of cases of Behçet’s disease. In: O’Duffy JD, Kokmen 
E, editors. Behçet’s disease: Basic and clinical aspects. New York: 
Marcel Dekker; 1991. p.303-8.
9. Altiparmak MR, Tanverdi M, Pamuk ON, Tunç R, Hamuryudan 
V. Glomerulonephritis in Behçet’s disease: report of seven cases 
and review of the literature. Clin Rheumatol 2002;21:14-8.
10. Fernandes PF, Júnior GB, Barros FA, Sousa DC, Franco LM, Pa-
trocínio RM. Behcet’s disease and IgA nephropathy: report of this 
association in a patient from Brazil and literature review. Invest 
Clin 2006;47:405-11.
11. Akutsu Y, Itami N, Tanaka M, Kusunoki Y, Tochimaru H, Takeko-
